Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
March 2020
-
Press Release
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to… -
Press Release
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,… -
Press Release
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory… -
Key Release
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at… -
Press Release
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk… -
Press Release
Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R… -
Press Release
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings… -
Key Release
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Key Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.… -
Key Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow… -
Press Release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to… -
Press Release
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…